Study summary
A PSMA radioligand added to hormone therapy delayed progression in newly treated disease
28%lower risk of progression or death
What was tested
Lutetium-177 PSMA-617 (Pluvicto), a radioactive drug that seeks out the PSMA protein on prostate cancer cells, added to hormone therapy (ADT plus an androgen receptor pathway inhibitor) for PSMA-positive metastatic hormone-sensitive prostate cancer.
What they found
- Progression or death occurred in 24% vs 30% at the interim analysis, a 28% lower relative risk.
- Median progression-free survival was not yet reached in either group.
What it means
Could move Lu-PSMA from late-stage treatment to the first year after diagnosis; survival results will decide.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.